干细胞临床应用现状及管理对策

中国生物工程杂志

2011, Vol. 31

Issue (8): 118-123

综述

干细胞临床应用现状及管理对策

王壮, 裴雪涛

军事医学科学院野战输血研究所全军干细胞与再生医学重点实验室北京 100850

Current Progress in Stem Cells for Clinical Application and Management Strategies

WANG Zhuang, PEI Xue-tao

Key Laboratory of Stem Cell and Regenerative Medicine of PLA,Beijing Institute of Transfusion Medicine,Beijing 100850,China

全文: PDF(497 KB) HTML

摘要：

干细胞研究及以其为基础的再生医学技术已经成为生物医学发展水平的重要标志之一。对于大量组织器官缺损或功能障碍患者构成的巨大医疗市场来说,干细胞与再生医学的研究与开发将产生重要影响,其进程也日益加快。干细胞根据来源和获得方式可分为胚胎干细胞、重编程干细胞及成体干细胞等类型,不同类型干细胞特点不同,技术成熟程度处于不同发展阶段,在可能的使用过程中风险规避的策略不同,不同来源的干细胞产品针对的临床适应症和准入标准也不尽相同。在概述这三类干细胞基础研究的基础上,对应用现状和发展趋势进行述评,并提出相关的管理策略。

关键词： 干细胞; 基础研究; 应用现状; 管理策略

Abstract:

Stem cells research and the technology of stem cell-based regenerative medicine have become one of the important parts for the development of biomedicines. The research and development of stem cell and regenerative medicine will have important impacts on the medical market for the patients with tissue and/or organ deficits or dysfunction. Based on the origin and the way obtained,stem cells are classcified as embryonic stem cells(ESCs),induced pluripotent stem cells(iPSCs)and adult stem cells(ASCs). Different types of stem cells may have different characteristics,and different risk potential for clinical use. The products of stem cells may have different clinical indication,and be reviewed by different standards. The current progress in the clinical application and management strategies of stem cells were reviewed

Key words: Stem cell Basic research Application status Management strategy

收稿日期: 2011-03-10 出版日期: 2011-08-25

ZTFLH:

Q819

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

引用本文:

王壮, 裴雪涛. 干细胞临床应用现状及管理对策[J]. 中国生物工程杂志, 2011, 31(8): 118-123.

WANG Zhuang, PEI Xue-tao. Current Progress in Stem Cells for Clinical Application and Management Strategies. China Biotechnology, 2011, 31(8): 118-123.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/ 或 https://manu60.magtech.com.cn/biotech/CN/Y2011/V31/I8/118

[1] Pozzobon M, Ghionzoli M, De Coppi P. ES, iPS, MSC, and AFS cells, stem cells exploitation for pediatric surgery: current research and perspective. Pediatr Surg Int, 2010,26(1):3-10.

[2] Stadtfeld M, Hochedlinger K. Induced pluripotency: history, mechanisms, and applications. Genes Dev, 2010,24(20):2239-2263.

[3] Giralt S A, Horowitz M, Weisdorf D, et al. Review of stem-cell transplantation for myelodysplastic syndrmoes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and Medicaid Services. J Clin Oncol, 2011, 29(5):566-572.

[4] Brignier A C, Gewirtz A M. Embryonic and adult stem cell therapy. J Allergy Clin Immunol, 2010,125(2): 336-344.

[5] Joannides A J, Chandran S. Human embryonic stem cells: an experimental and therapeutic resource for neurological disease. J Neurol Sci, 2008,265(1-2):84-88.

[6] Schroeder I S, Rolletschek A, Blyszczuk P, et al. Differentiation of mouse embryonic stem cells to insulin-producing cells. Nat Protoc, 2006,1(2):495-507.

[7] Gonzales C, Pedrazzini T. Progenitor cell therapy for heart disease. Exp Cell Res, 2009,315(18):3077-3085.

[8] Sharp J, Frame J, Siegenthaler M, et al. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants improve recovery after cervical spinal cord injury. Stem Cells, 2010,28(1):152-163.

[9] Rosenzweig A. Cardiac cell therapy——mixed results from mixed cells. N Engl J Med, 2006,355(12):1274-1277.

[10] Assmus B, Honold J, Schachinger V, et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med, 2006,355(12):1222-1232.

[11] Laguna Goya R, Kuan W L, Barker R A. The future of cell therapies in the treatment of Parkinson's disease. Expert Opin Biol Ther, 2007,7(10):1487-1498.

[12] Deschaseaux F, Pontikoglou C, Sensebe L. Bone regeneration: the stem/progenitor cells point of view. J Cell Mol Med, 2010,14(1-2):103-115.

[13] Kisseleva T, Gigante E, Brenner D A. Recent advances in liver stem cell therapy. Curr Opin Gastroenterol, 2010,26(4):395-402.

[14] Gekas C, Graf T. Induced pluripotent stem cell-derived human platelets: one step closer to the clinic. J Exp Med, 2010,207(13):2781-2784.

[15] 国家卫生部. 医疗技术临床应用管理办法. 2009. Chinese Ministry of Public Health. Management Practices of the Clinical Application of Medical Technology. 2009.

[16] 中国食品与药品管理局. 人体细胞治疗研究和制剂质量控制技术指导原则. 2003. State Food and Drug Administration. Human Cell Therapy Research and Quality Control Guidelines of the Preparation. 2003.

[1]	钱昱,丁晓雨,刘志强,袁增强. 基因修饰人多能干细胞的高效单克隆建系方法[J]. 中国生物工程杂志, 2021, 41(8): 33-41.
[2]	李开秀,司维. 间充质干细胞来源的外泌体治疗炎症性肠病研究进展^*[J]. 中国生物工程杂志, 2021, 41(7): 66-73.
[3]	王宇轩,陈婷,张永亮. MiR-148生物学功能研究进展^*[J]. 中国生物工程杂志, 2021, 41(7): 74-80.
[4]	赵久梅,王哲,李学英. 调控软骨形成的信号通路及相关因子在骨髓间充质干细胞骨向分化中的作用^*[J]. 中国生物工程杂志, 2021, 41(10): 62-72.
[5]	陈飞,王晓冰,徐增辉,钱其军. 干细胞改善糖尿病的分子机制及临床研究进展[J]. 中国生物工程杂志, 2020, 40(7): 59-69.
[6]	戴奇男,张景红. 肿瘤多药耐药与自噬、DNA修复和肿瘤干细胞相关的分子机制研究进展 ^*[J]. 中国生物工程杂志, 2020, 40(4): 69-77.
[7]	苑亚坤,刘广洋,刘拥军,谢亚芳,吴昊. 间充质干细胞基础研究与临床转化的中美比较[J]. 中国生物工程杂志, 2020, 40(4): 97-107.
[8]	杨丹,田海山,李校堃. 成纤维细胞生长因子5的研究进展 ^*[J]. 中国生物工程杂志, 2020, 40(3): 117-124.
[9]	李玉,张晓. 日本细胞治疗监管双轨制的经验及启示 ^*[J]. 中国生物工程杂志, 2020, 40(1-2): 174-179.
[10]	陈利军,屈晶晶,项春生. 间充质干细胞在2019新型冠状病毒肺炎(COVID-19)中的治疗潜能、临床研究与应用前景^*[J]. 中国生物工程杂志, 2020, 40(11): 43-55.
[11]	邱丹丹,陆彩霞,代解杰. 诱导多能干细胞来源的肝细胞在HCV感染模型中的应用^*[J]. 中国生物工程杂志, 2020, 40(11): 67-72.
[12]	朱永朝,陶金,任萌萌,熊燃,何亚琴,周瑜,卢震辉,杜勇,杨芝红. 自噬抑制肿瘤坏死因子α诱导人胎盘胎儿来源间充质干细胞发生凋亡 ^*[J]. 中国生物工程杂志, 2019, 39(9): 62-67.
[13]	李欣,赵中利,罗晓彤,曹阳,张立春,于永生,金海国. 诱导多能干细胞向雄性生殖细胞分化诱导物的研究进展 ^*[J]. 中国生物工程杂志, 2019, 39(4): 94-100.
[14]	范月蕾,陆娇,陈大明,毛开云. 干细胞专利价值评估与转移转化对策研究 ^*[J]. 中国生物工程杂志, 2019, 39(1): 99-106.
[15]	施文雯,张蕾. 力学微环境影响间充质干细胞分化的研究现状 ^*[J]. 中国生物工程杂志, 2018, 38(8): 76-83.

Viewed

Full text

Abstract

Cited

Shared

Discussed